Guard Therapeutics International AB (publ)
SSE:GUARD.ST
19.8 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.033 | 0.715 | 1.25 | 0.029 |
| Cost of Revenue
| 0.015 | 0.015 | 0.015 | 0.161 | 0.29 | 22.519 | 2.39 | 1.989 | 0.841 | -11.004 | -7.504 | -5.953 | -2.838 |
| Gross Profit
| -0.015 | -0.015 | -0.015 | -0.161 | -0.29 | -22.519 | -2.39 | -1.989 | -0.841 | 11.037 | 8.219 | 7.203 | 2.867 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 334.455 | 11.495 | 5.762 | 99.773 |
| Reseach & Development Expenses
| 105.773 | 104.812 | 75.327 | 35.415 | 37.561 | 73.688 | 55.205 | 44.822 | 22.577 | 9.948 | 0 | 0 | 0 |
| General & Administrative Expenses
| 5.383 | 4.974 | 3.696 | 3.081 | 3.408 | 4.746 | 3.507 | 4.329 | 2.522 | 13.264 | 9.115 | 5.845 | 0 |
| Selling & Marketing Expenses
| 3.766 | 3.843 | 2.26 | 1.923 | 3.315 | 7.618 | 8.768 | 5.434 | 4.999 | 2.522 | 0 | 0 | 0 |
| SG&A
| 9.134 | 8.817 | 5.956 | 5.004 | 6.723 | 12.364 | 12.275 | 9.763 | 7.521 | 13.264 | 9.115 | 5.845 | 0 |
| Other Expenses
| 0 | 0 | 0 | -0.143 | 0 | 0 | 0 | -0.163 | -0.105 | 3.637 | 3.676 | 3.493 | 3.809 |
| Operating Expenses
| 114.907 | 113.629 | 81.283 | 40.276 | 44.284 | 86.052 | 67.48 | 54.422 | 29.993 | 16.901 | 12.791 | 9.338 | 3.809 |
| Operating Income
| -114.922 | -114.921 | -81.9 | -40.277 | -44.284 | -86.052 | -67.48 | -54.422 | -29.993 | -5.898 | -4.572 | -2.135 | -0.942 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -178.727 | -6.394 | -1.708 | -32.785 |
| Total Other Income Expenses Net
| 1.599 | 2.082 | -0.13 | -0.007 | -0.872 | -0.656 | -0.163 | -0.017 | -2.458 | -0.267 | -0.592 | 0.04 | -0.023 |
| Income Before Tax
| -113.323 | -112.839 | -82.03 | -40.284 | -45.156 | -86.708 | -67.643 | -54.439 | -32.451 | -6.164 | -5.164 | -2.095 | -0.965 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -186.788 | -7.222 | -1.676 | -33.586 |
| Income Tax Expense
| 114.807 | -2.083 | 0.13 | 0.007 | 0.872 | 0.656 | 0.163 | -2.36 | -0.037 | 0.267 | 0.592 | -0.04 | 0.023 |
| Net Income
| -113.323 | -110.756 | -82.16 | -40.291 | -46.028 | -86.708 | -67.643 | -52.079 | -32.415 | -6.164 | -5.164 | -2.095 | -0.965 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -186.788 | -7.222 | -1.676 | -33.586 |
| EPS
| -11.26 | -15.72 | -18.41 | -12.15 | -22.16 | -2.69 | -5.07 | -10.65 | -8.06 | -1.88 | -2.49 | -1.01 | -0.46 |
| EPS Diluted
| -11.26 | -15.72 | -18.41 | -12.15 | -22.16 | -2.69 | -5.07 | -10.65 | -8.06 | -1.88 | -2.49 | -1.01 | -0.46 |
| EBITDA
| -114.907 | -112.838 | -82.029 | -40.116 | -39.902 | -63.534 | -65.529 | -52.433 | -31.578 | -5.791 | -4.39 | -2.076 | -0.936 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -175.485 | -6.14 | -1.661 | -32.589 |